Osimertinib Now Standard in Frontline EGFR+ NSCLC, But Potential for Progress Remains
Mary J. Fidler, MD, discusses how recent research has impacted the EGFR-mutant non–small cell lung cancer landscape.
Related Articles
SUPRAME Trial Seeks to Establish IMA203 as the First TCR-Based Therapy for Cutaneous Melanoma
The phase 3 SUPRAME trial is comparing IMA203 vs investigator’s choice of therapy in patients with pretreated unresectable or metastatic cutaneous melanoma.
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL
Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.
Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL
The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.
BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer
FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.
AlloHSCT in AML: When, Why, and for Whom?
Panelists discuss how identifying appropriate candidates for allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) involves evaluating remission status, relapse risk based…